To review the literature concerning the history, development, and therapeutic uses of bisphosphonates.
DATA SOURCES:
English-language articles were identified through a search of MEDLINE (through December 2004) using the key word bisphosphonate. Reference lists of pivotal studies, reviews, and full prescribing information for the approved agents were also examined.
STUDY SELECTION AND DATA EXTRACTION:
Selected studies included those that discussed the discovery and initial applications of bisphosphonates, as well as their historical development, pharmacokinetic and pharmacodynamic properties, and current therapeutic uses.
DATA SYNTHESIS:
Bisphosphonates structurally resemble pyrophosphates (naturally occurring polyphosphates) and have demonstrated similar physicochemical effects to pyrophosphates. In addition, bisphosphonates reduce bone turnover and resist hydrolysis when administered orally. The information gained from initial work with etidronate generated a considerable scientific effort to design new and more effective bisphosphonates. The PCP moiety in the general bisphosphonate structure is essential for binding to hydroxyapatite and allows for a number of chemical variations by changing the 2 lateral side chains (designated R1 and R2). The R1 side chain determines binding affinity to hydroxyapatite, and the R2 side chain determines antiresorptive potency. Accordingly, each bisphosphonate has its own characteristic profile of activity.
CONCLUSIONS:
The bisphosphonates reduce bone turnover, increase bone mass, and decrease fracture risk and therefore have a significant place in the management of skeletal disorders including osteoporosis, Paget's disease, bone metastases, osteogenesis imperfecta, and heterotopic ossification.
SaagKG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am2003;32:135–57, vii.
3.
SelbyPLDavieMWRalstonSHStoneMD. Guidelines on the management of Paget's disease of bone. Bone2002;31: 366–73.
4.
ColemanRE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev2001;27: 165–76.
5.
BuehrerTReitemeyerR.The inhibiting action of minute amounts of sodium hexametaphosphate on the precipitation of calcium carbonate from ammoniacal solutions. J Phys Chem1940;44: 552–74.
6.
FleischHBisazS.Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol1962;203: 671–5.
7.
FleischHRussellRG. A review of the physiological and pharmacological effects of pyrophosphate and diphosphonates on bones and teeth. J Dent Res1972;51: 324–32.
8.
DavisMAJonesAL. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med1976;6: 19–31.
9.
FleischHRussellRGFrancisMD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science1969;165: 1262–4.
10.
FleischHRussellRBisazSCaseyPMuhlbauerRC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res1968;2(suppl):10-A.
11.
JungABisazSFleischH.The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res1973;11: 269–80.
12.
FleischHARussellRGBisazSMuhlbauerRCWilliamsDA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest1970;1: 12–8.
13.
CaseyPACaseyGFleischHFusselRG. The effect of polyphloretin phosphate, polyoestradiol phosphate, a diphosphonate and a polyphosphate on calcification induced by dihydrotachysterol in skin, aorta and kidney of rats. Experientia1972;28: 137–8.
14.
SchenkRMerzWAMuhlbauerRRussellRGFleischH.Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res1973;11: 196–214.
15.
BassettCADonathAMacagnoFPreisigRFleischHFrancisMD. Diphosphonates in the treatment of myositis ossificans (letter). Lancet1969;2:845.
16.
RussellRGCroucherPIRogersMJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int1999;9(suppl 2):S66–80.
17.
van BeekERLowikCWEbetinoFHPapapoulosSE. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone1998;23: 437–42.
18.
WattsNB. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am1998;27: 419–39.
19.
GeddesADD'SouzaSMEbetinoFHIbbotsonKJ. Bisphosphonates: Structure-activity relationships and therapeutic implications. In: HeerscheJNMKanisJA, eds. Bone and Mineral Research. Amsterdam: Elsevier Science, 1994:265–74.
20.
RodanGAFleischHA. Bisphosphonates: Mechanisms of action. J Clin Invest1996;97: 2692–6.
21.
LehenkariPPKellinsalmiMNapankangasJPYlitaloKVMonkkonenJRogersMJFurther insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol2002;61: 1255–62.
22.
FrithJCMonkkonenJAuriolaSMonkkonenHRogersMJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum2001;44:2201–10.
23.
FleischH.Bisphosphonates: Mechanisms of action. Endocr Rev1998;19: 80–100.
24.
BergstromJDBostedorRGMasarachiaPJReszkaAARodanG.Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys2000;373: 231–41.
25.
DunfordJEThompsonKCoxonFPLuckmanSPHahnFMPoulterCDStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther2001;296: 235–42.
26.
GertzBJHollandSDKlineWFMatuszewskiBKFreemanAQuanHStudies of the oral bioavailability of alendronate. Clin Pharmacol Ther1995;58: 288–98.
27.
LinJH. Bisphosphonates: A review of their pharmacokinetic properties. Bone1996;18: 75–85.
28.
MitchellDYBarrWHEusebioRAStevensKADukeFPRussellDARisedronate pharmacokinetics and intra-and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res2001;18: 166–70.
29.
VillikkaKPerttunenKRosnellJIkavalkoHVahoHPylkkanenL.The absolute bioavailability of clodronate from two different oral doses. Bone2002;31: 418–21.
30.
RavnPNeugebauerGChristiansenC.Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone2002;30: 320–4.
31.
MitchellDYHeiseMAPalloneKAClayMENesbittJDRussellDAThe effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol1999;48: 536–42.
32.
LinJHDugganDEChenIWEllsworthRL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos1991;19: 926–32.
33.
SatoMGrasserWEndoNAkinsRSimmonsHThompsonDDBisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest1991;88: 2095–105.
34.
MitchellDYEusebioRAAxelrodDWHicksKRRussellDAKamraLCRisedronate pharmacokinetics following single and multiple dose intravenous administration (abstract). Bone1997;20:100S.
35.
CocquytVKlineWFGertzBJVan BelleSJHollandSDDeSmetMPharmacokinetics of intravenous alendronate. J Clin Pharmacol1999;39: 385–93.
36.
KhanSAKanisJAVasikaranSKlineWFMatuszewskiBKMcCloskeyEVElimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res1997;12: 1700–7.
GattiDAdamiS.New bisphosphonates in the treatment of bone diseases. Drugs Aging1999;15: 285–96.
39.
MitchellDYEusebioRASacco-GibsonNAPalloneKAKellySCNesbittJDDose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol2000;40: 258–65.
MitchellDYSt. PeterJVEusebioRAPalloneKAKellySCRussellDAEffect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol2000;49: 215–22.
44.
BlackDMCummingsSRKarpfDBCauleyJAThompsonDENevittMCRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348: 1535–41.
45.
CummingsSRBlackDMThompsonDEApplegateWBBarrett-ConnorEMuslinerTAEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA1998;280: 2077–82.
46.
BlackDMThompsonDEBauerDCEnsrudKMuslinerTHochbergMCFracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab2000;85: 4118–24.
47.
BoneHGHoskingDDevogelaerJPTucciJREmkeyRDToninoRPTen years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med2004;350: 1189–99.
48.
RizzoliRGreenspanSLBoneG3rdSchnitzerTJWattsNBAdamiSTwo-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res2002;17: 1988–96.
49.
RosenCJHochbergMCBonnickSLMcClungMMillerPBroySTreatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized, double-blind study. J Bone Min Res2005;20: 141–51.
50.
CummingsSRKarpfDBHarrisFGenantHKEnsrudKLaCroixAZImprovement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med2002;112: 281–9.
51.
WattsNBCooperCLindsayREastellRManhartMDBartonIPRelationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom2004;7: 255–61.
52.
LiZMeredithMHoseyniMS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med2001;20: 3175–88.
53.
OrwollEEttingerMWeissSMillerPKendlerDGrahamJAlendronate for the treatment of osteoporosis in men. N Engl J Med2000;343: 604–10.
54.
SaagKGEmkeyRSchnitzerTJBrownJPHawkinsFGoemaereSAlendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med1998;339: 292–9.
55.
SirisEWeinsteinRSAltmanRConteJMFavusMLombardiAComparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab1996;81: 961–7.
56.
WalshJPWardLCStewartGOWillRKCriddleRAPrinceRLA randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone2004;34: 747–54.
57.
ReidIRNicholsonGCWeinsteinRSHoskingDJCundyTKotowiczMABiochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med1996;101: 341–8.
58.
KhanSAVasikaranSMcCloskeyEVBenetonMNRogersSCoultonLAlendronate in the treatment of Paget's disease of bone. Bone1997;20: 263–71.
59.
MillerPDBrownJPSirisESHoseyniMSAxelrodDWBekkerPJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med1999;106: 513–20.
60.
HaslingCCharlesPMosekildeL.Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med1987;82: 51–4.
61.
SingerFRRitchPSLadTERingenbergQSSchillerJHReckerRRTreatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med1991;151: 471–6.
62.
FloresJFRudeRKChapmanRABelaniCPChangAYPritchardJDEvaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer1994;73: 2527–34.
63.
AdachiJDBensenWGBrownJHanleyDHodsmanAJosseRIntermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med1997;337: 382–7.
64.
PittPLiFToddPWebberDPackSMonizC.A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax1998;53: 351–6.
65.
SebaldtRJIoannidisGAdachiJDBensenWGBianchiFCividinoA36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol1999;26: 1545–9.
66.
ChesnutICSkagAChristiansenCReckerRStakkestadJAHoisethAEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res2004;19: 1241–9.
67.
TankoLBFelsenbergDCzerwinskiEBurdeskaAJonkanskiIHughesCOral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med2003;254: 159–67.
68.
CooperCEmkeyRDMcDonaldRHHawkerGBianchiGWilsonKEfficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab2003;88: 4609–15.
69.
MillerPDreznerMDelmasPStakkestadJHughesCBonvoisinBMonthly oral ibandronate is at least as effective as oral daily ibandronate in postmenopausal osteoporosis: 1-year results from MOBILE (abstract). J Bone Miner Res2004;19(suppl 1):S94.
70.
StakkestadJABenevolenskayaLIStepanJJSkagANordbyAOefjordEIntravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis2003;62: 969–75.
71.
RingeJDDorstAFaberHIbachKSorensonF.Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos Int2003;14: 801–7.
72.
PecherstorferMSteinhauerEURizzoliRWetterwaldMBergstromB.Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate. Support Care Cancer2003;11: 539–47.
73.
GucalpRRitchPWiernikPHSarmaPRKellerARichmanSPComparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol1992;10: 134–42.
74.
TrombettiAArlotMThevenonJUebelhartBMeunierPJ. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed1999;66: 467–76.
75.
VasireddySTalwalkarAMillerHMehanRSwinsonDR. Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. Clin Rheumatol2003;22: 376–80.
76.
IsmailAAFoxPStampTCDhillonVCrispAJMacGregorA.Treatment of Paget's disease of bone with intravenous pamidronate: Comparison of 2 different modes of treatment. J Rheumatol1997;24: 2266–7.
77.
CundyTWattieDKingAR. High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int1996;58: 6–8.
78.
TucciJRBonthaS.Intravenously administered pamidronate in the treatment of Paget's disease of bone. Endocr Pract2001;7: 423–9.
79.
HarrisSTWattsNBGenantHKMcKeeverCDHangartnerTKellerMEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA1999;282: 1344–52.
80.
ReginsterJMinneHWSorensenOHHooperMRouxCBrandiMLRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int2000;11: 83–91.
81.
RouxCSeemanEEastellRAdachiJJacksonRDFelsenbergDEfficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin2004;20: 433–9.
82.
HarringtonJTSte-MarieLGBrandiMLCivitelliRFardellonePGrauerARisedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int2004;74: 129–35.
83.
SorensenOHCrawfordGMMulderHHoskingDJGennariCMellstromDLong-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone2003;32: 120–6.
84.
MellstromDDSorensenOHGoemaereSRouxCJohnsonTDChinesAA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int2004;75: 462–8.
85.
McClungMRGeusensPMillerPDZippelHBensenWGRouxCEffect of risedronate on the risk of hip fracture in elderly women. N Engl J Med2001;344: 333–40.
86.
BrownJPKendlerDLMcClungMREmkeyRDAdachiJDBologneseMAThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int2002;71: 103–11.
87.
HarrisSTWattsNBLiZChinesAAHanleyDABrownJP. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin2004;20: 757–64.
88.
WattsNBLindsayRLiZKasibhatlaCBrownJ.Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int2003;14: 437–41.
89.
ReidDMHughesRALaanRFSacco-GibsonNAWenderothDHAdamiSEfficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res2000;15: 1006–13.
90.
CohenSLevyRMKellerMBolingEEmkeyRDGreenwaldMRisedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum1999;42: 2309–18.
91.
WallachSCohenSReidDMHughesRAHoskingDJLaanRFEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int2000;67: 277–85.
92.
FraserWDStampTCCreekRASawyerJPPicotC.A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J1997;73: 496–502.
93.
McClungMRTouCKGoldsteinNHPicotC.Tiludronate therapy for Paget's disease of bone. Bone1995;17(5 suppl):493S–6S.
94.
RouxCGennariCFarreronsJDevogelaerJPMulderHKruseHPComparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum1995;38: 851–8.
95.
ReginsterJYTrevesRRenierJCAmorBSanyJEthgenDEfficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. J Bone Miner Res1994;9: 615–9.
96.
ReginsterJYChristiansenCRouxCFechtenbaumJRouillonATouKP. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int2001;12: 169–77.
97.
MajorPLortholaryAHonJAbdiEMillsGMenssenHDZoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19: 558–67.
98.
RosenLSGordonDKaminskiMHowellABelchAMackeyJZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J2001;7: 377–87.
99.
ReidIRBrownJPBurckhardtPHorowitzZRichardsonPTrechselUIntravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med2002;346: 653–61.
100.
Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003.
101.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum2001;44: 1496–503.
102.
YoodRAEmaniSReedJILewisBECharpentierMLydickE.Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int2003;14: 965–8.
103.
CramerJAmonkarMHebbornASuppapanyaN.Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?(abstract). J Bone Miner Res2004;19 (suppl 1): S448.
104.
ReckerRGallagherRAmonkarMSmithJMacCosbeP.Medication persistence is better with weekly bisphosphonates, but it remains suboptimal (abstract). J Bone Miner Res2004;19(suppl 1):S172.
105.
CummingsSRBatesDBlackDM. Clinical use of bone densitometry: Scientific review. JAMA2002;288: 1889–97.
106.
AmmannPRizzoliR.Bone strength and its determinants. Osteoporos Int2003;14(suppl 3):S13–8.
107.
BorahBDufresneTEChmielewskiPAJohnsonTDChinesAManhartMD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional micro-computed tomography. Bone2004;34: 736–46.
108.
EastellRBartonIHannonRAChinesAGarneroPDelmasPD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res2003;18: 1051–6.
